YITU Attended ICCV 2019 with Self-developed Cloud AI Chip, Showcasing Integrated Software and Hardware Strength
1.11.2019 13:00:00 EET | Business Wire | Press release
The 17th International Conference on Computer Vision (ICCV 2019) was convened in Seoul, South Korea this week. YITU Technology attended the conference with its latest researches. Known as the world’s top-notch computer vision conference, ICCV is held once every two years, of which the papers and topics manifest the highest research level and technical growth trend in the field of computer vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191101005240/en/
YITU AI chip QuestCore TM (Photo: Business Wire)
As a globally leading artificial intelligence company, YITU has been always standing at the frontier of AI innovations. From October 29th to November 1st, AI researchers from YITU present their up-to-date research findings and industrial practices at the ICCV 2019, including QuestCoreTM, a cloud AI chip developed by YITU, so as to communicate with and learn from a wider range of research communities.
“The peak of artificial intelligence algorithm performance has shifted from academia to industry,” said Dr. Yan Shuicheng, CTO of YITU, “Academia and industry need in-depth cooperation, to better boost increasing peak performance of the entire AI ecological algorithm.”
As a world-known scholar in computer vision and machine learning, Dr. Yan joined YITU in August this year, the company's strong R&D and engineering strength is one of the important reasons for him to join. Dr. Yan, as an IEEE Fellow, IAPR Fellow and ACM Distinguished Scientist, has published more than 600 papers in top international journals and conferences, with more than 40,000 citations, H-index 98.
YITU released its self-developed cloud AI chip QuestCoreTM in May, 2019. Integrated with its world-class AI algorithm and advanced chip design philosophy, it is so far the most intelligent and cost-effective video analysis chip in the world. This chip indicates a successful practice of YITU to follow the strong coupling trend between AI algorithms and chip design. Relevant achievements are also exhibited on ICCV 2019.
According to data from Tsinghua University, computer vision applications accounted for nearly 35% of the total artificial intelligence applications in 2019, and have become an important support for the development of various industries.
YITU is building the Visual Computing National New Generation Artificial Intelligence Open Innovation Platforman, a national AI infrastructure, to align with the developers of algorithm, chip and product, and provide full chain optimization services covering algorithm, chip and entire tool chain.
“We will help to enhance the overall performance of visual computing smart industry solution,” said Dr. Yan Shuicheng. “Help to integrate development experience and domain knowledge, and promote industrial innovation and cooperation."
About YITU
YITU Technology is one of the few startups in the world that has pioneered many cutting-edge technologies in many critical Artificial Intelligent (AI) fields such as computer vision, speech recognition, natural language processing, intelligent decision-making and AI chips.
YITU Technology is dedicated to advancing breakthrough technologies in AI. Powered by world-class AI algorithms, YITU's self-developed AI chip QuestCore™ can be applied to a variety of scenarios to provide cost-effective and market-competitive solutions. YITU is the only company worldwide to be awarded championship in facial recognition vendor test three times by National Institute of Standards and Technology (NIST), as well as first place in the test hosted by the Intelligence Advanced Research Projects Activity (IARPA). YITU’s self-developed speech recognition technology has been tested to be best-in-class for the Mandarin language. Nature Medicine, a leading academic journal, published on YITU’s latest breakthrough in intelligent pediatric diagnostic technology based on NLP this February, which has been so far the highest-level paper in the field of artificial intelligence research in China.
Leveraging AI technology, YITU is empowering diverse industries. It provides world-leading innovative technologies and products in several sectors including Intelligent City, Smart Finance, Intelligent Healthcare, Smart Retail, AI Chips and AI Pharmaceuticals. YITU is so far the only AI company nationwide able to provide intelligent management technology in mega-cities and complex conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191101005240/en/
Contact information
Yitu Tech
Contact name: Alice Deng
Tel:021 - 52559588
Email:media@yitu-inc.com
Website: https://www.yitutech.com/en
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom